Back to top
more

Pfizer (PFE)

(Delayed Data from NYSE)

$29.22 USD

29.22
24,234,574

-0.05 (-0.17%)

Updated Oct 18, 2024 04:00 PM ET

After-Market: $29.21 -0.01 (-0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 14% (34 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Pfizer Ibrance sNDA Accepted by FDA under Priority Review

by Zacks Equity Research

Pfizer Inc.'s (PFE) supplemental new drug application (sNDA) to convert accelerated approval for its breast cancer drug, Ibrance, to regular approval was accepted by the FDA under priority review.

    J&J Resumes Talks with Actelion: Did Sanofi Just Lose Out?

    by Zacks Equity Research

    In an interesting turn of events, Johnson & Johnson (JNJ) announced that it is once again discussing a possible transaction with Swiss biotechnology company Actelion Ltd. (ALIOF).

      Pfizer (PFE) Nimenrix Vaccine's Label Expanded in the EU

      by Zacks Equity Research

      Pfizer Inc. (PFE) announced that the European Commission has approved an expanded indication for its meningococcal vaccine, Nimenrix.

        Allergan to Buy LifeCell to Boost Regenerative Medicine Suite

        by Zacks Equity Research

        Allergan plc (AGN) announced that it has signed a definitive agreement to acquire LifeCell, the regenerative medicine unit of Texas-based privately held company Acelity for $2.9 billion in cash.

          Merck Keytruda Gets CHMP Nod for First-Line Lung Cancer

          by Zacks Equity Research

          Merck & Co., Inc. (MRK) announced that its anti-PD-1 therapy, Keytruda, was rendered a positive opinion in the EU for the first-line treatment of metastatic lung cancer.

            Pfizer Chantix Label Warning Lifted in U.S.; to Add New Data

            by Zacks Equity Research

            Pfizer, Inc. (PFE) announced that the FDA has lifted a boxed warning about neuropsychiatric side effects from the label of its smoking cessation drug, Chantix.

              Arpita Dutt headshot

              Pharma Stock Roundup: Lilly Up on Guidance, Merck Awarded $2.54B in HCV Case

              by Arpita Dutt

              Lilly (LLY) was among the biggest gainers among major pharma stocks last week with the company providing better-than-expected guidance for 2017.

                Swarup Gupta headshot

                Dow 30 Stock Roundup: Boeing, GE Raise Dividends; ExxonMobil Gets New CEO

                by Swarup Gupta

                The Dow enjoyed a week of strong gains on rising expectations about the likely industry friendly policies of the Trump administration.

                  Big Pharma Face Off: Is Merck More Attractive than J&J?

                  by Zacks Equity Research

                  Johnson & Johnson (JNJ) and Merck & Co. Inc. (MRK) are some of the better-performing large-cap pharma stocks

                    Pfizer: FDA Approves Eczema Ointment; Xtandi Fails Study

                    by Zacks Equity Research

                    Pfizer, Inc. (PFE) announced that it received FDA approval for crisaborole topical ointment to treat mild-to-moderate eczema, or atopic dermatitis, in patients two years and older. The ointment will be sold under the brand name Eucrisa.

                      Will Buyback ETFs Gain Big on Overseas Cash Repatriation?

                      by Zacks Equity Research

                      With Donald Trump winning the U.S. elections, a plethora of buybacks are expected to hit the market.

                        J&J (JNJ) Ends Deal Talks with Actelion: Will Sanofi Gain?

                        by Zacks Equity Research

                        On Tuesday, Johnson & Johnson (JNJ) announced that it has ended talks regarding a possible transaction with Swiss biotechnology company, Actelion Ltd. (ALIOF), reportedly for a disagreement over the purchase price.

                          Lilly/AstraZeneca Expand Alzheimer Disease Collaboration

                          by Zacks Equity Research

                          Eli Lilly and Company (LLY) and AstraZeneca plc (AZN) expanded their existing collaboration to develop the second treatment for Alzheimer's disease, MEDI1814

                            Pfizer (PFE) Fined for Price Hike of Anti-Epilepsy Drug in UK

                            by Zacks Equity Research

                            Pfizer (PFE) fined for hiking price of an anti-epilepsy drug by up to 2,600% by the Competition and Markets Authority of the UK.

                              Arpita Dutt headshot

                              Should Biotech Investors Worry About Donald Trump?

                              by Arpita Dutt

                              It looks like biotech investors may have heaved a sigh of relief a bit too early when Presidential election results were announced last month.

                                Novartis (NVS) Zykadia Positive in Phase III ASCEND-4 Study

                                by Zacks Equity Research

                                Novartis (NVS) announced results from the phase III ASCEND-4 study on Zykadia, for the treatment of patients with advanced ALK+ NSCLC.

                                  Pfizer Leukemia Drug Meets Primary Endpoint in Phase III

                                  by Zacks Equity Research

                                  Pfizer Inc. (PFE) and partner Avillion LLP announced that a phase III study (BFORE) evaluating its marketed drug Bosulif in the first-line setting met the primary endpoint

                                    Pfizer (PFE) Presents Favorable Data on Leukemia Candidate

                                    by Zacks Equity Research

                                    Pfizer Inc. (PFE) announced new positive data from a randomized phase II study on its investigational candidate glasdegib (PF-04449913) for the first-line treatment of patients with acute myeloid leukemia (AML).

                                      Merck's Keytruda Gets Priority Review for Hodgkin Lymphoma

                                      by Zacks Equity Research

                                      Merck & Co., Inc.'s (MRK) supplemental Biologics License Application (sBLA) ??? the second this week ??? for its anti-PD-1 therapy, Keytruda, has been accepted for priority review by the FDA.

                                        Pfizer Offers Positive Phase III Data on Pediatric Epilesy Drug

                                        by Zacks Equity Research

                                        Pfizer Inc. (PFE) announced positive top-line results from a phase III study evaluating its marketed drug, Lyrica (pregabalin), as adjunctive therapy for the treatment of pediatric patients suffering from epilepsy with partial-onset seizures.

                                          Tirthankar Chakraborty headshot

                                          5 Top Performing S&P 500 Stocks of November

                                          by Tirthankar Chakraborty

                                          President-elect Donald Trump has proposed a raft of fiscal-stimulus measures, which has pushed the S&P 500 to almost an all-time high in November

                                            Pfizer's Herceptin Biosimilar Meets Primary Endpoint in Study

                                            by Zacks Equity Research

                                            Pfizer, Inc. (PFE) recently announced that its experimental biosimilar of Roche Holding AG's (RHHBY) breast cancer drug - Herceptin - has reached the primary endpoint in a pivotal study.

                                              ARIAD's Leukemia Drug Iclusig Gets Full Approval in U.S.

                                              by Zacks Equity Research

                                              ARIAD Pharmaceuticals, Inc. (ARIA) announced that the FDA has granted a full approval to its leukemia drug, Iclusig (ponatinib), following its successful completion of the commitments made on accelerated approval in Dec 2012.

                                                Pfizer/Merck KGaA: Priority Review for Cancer Drug Avelumab

                                                by Zacks Equity Research

                                                Pfizer, Inc. (PFE) and German partner Merck KGaA (MKGAF) announced that the Biologics License Application for avelumab, has been accepted for priority review by the FDA.

                                                  J&J (JNJ) Stands Tall in 2016: Reasons for Outperformance

                                                  by Zacks Equity Research

                                                  Johnson & Johnson's (JNJ) share price is up 9.5% in the year-to-date period. This compares favorably with the 8.0% fall for the Zacks classified Large-Cap Pharma industry.